Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Data shows Cambridge biotech’s muscular dystrophy treatment is effective

10/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzmvndyvmzq0l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

A Cambridge biotechnology company developing a treatment for a severe form of muscular dystrophy that progresses rapidly presented three years of data Thursday that show the drug is helping to slow the effects of the fatal, muscle-wasting disease.

With the positive results, Sarepta Therapeutics will seek approval from the Food and Drug Administration later this year with the goal of selling the drug, called eteplirsen, in 2015, to treat the disease known as Duchenne muscular dystrophy. If approved, it would be Sarepta’s first commercial drug.

“We’re very encouraged by this data,” Sarepta’s chief executive, Chris Garabedian, said in an interview. “This is more evidence that the FDA can look at to positively review eteplirsen’s treatment benefits.”

Duchenne muscular dystrophy occurs in about 1 of every 3,500 boys, destroying muscle function and quality of life over time. The disease moves swiftly, robbing most boys of the ability to walk by their teen years, and damaging their respiratory muscles. Duchenne patients typically do not live past their 20s.

This article has been extracted from http://www.bostonglobe.com, please click on this link to read the article in full http://www.bostonglobe.com/business/2014/07/10/data-shows-cambridge-biotech-muscular-dystrophy-treatment-effective/8qULRRssaguT8qFw26tqXP/story.html

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdkvmjkvmdgvmtmvmjkvmjgyl1vudgl0bgvkigrlc2lnbiaomjuplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Are PSLs a Blocker or an Enabler?

2017-10-02 11:00:00 +0100

The use of a Preferred Supplier List (PSL) was intended to support and strengthen relationships and performance between organisations and their third party suppliers. As the technical landscape continues to evolve at rapid rate recruitment and demand for new skills becomes more intense. Are PSLs still the solution or an obstacle to sourcing the right talent? The traditional PSL A dedicated list of partners intended to guarantee quality and availability ...

W1siziisijiwmtcvmdkvmjevmdgvndmvmduvmtmxl1vudgl0bgvkigrlc2lnbiaomjmplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Why do we punish the victims of hacking?

2017-09-21 09:00:00 +0100

Hacks occur every 39 seconds, with 95% of them targeting governments, retailers and the tech industry. If the hackers are caught, they'll face prison time under the Computer Misuse Act. More often than not, the businesses who are victims of those attacks expose themselves to punishment of their own. The laws that determine the duty of protection owed to businesses and their customers is both vague and broad, making them question just how much protection...